To Stimulate or Withdraw? A Cost-Utility Analysis of Recombinant Human Thyrotropin<i>Versus</i>Thyroxine Withdrawal for Radioiodine Ablation in Patients with Low-Risk Differentiated Thyroid Cancer in the United States

Abstract

In the United States, the cost-effectiveness of rhTSH for ablation in patients with low-risk differentiated thyroid cancer is highly dependent on potential variations in cost of rhTSH, rates of remnant ablation, time off work, and quality of life.